Merck Net Acquisitions/Divestitures 2012-2026 | MRK
Merck annual/quarterly net acquisitions/divestitures history and growth rate from 2012 to 2026. Net acquisitions/divestitures can be defined as the total change in cash resulting from both investments in businesses and sales of businesses or business segments.
- Merck net acquisitions/divestitures for the quarter ending March 31, 2026 were $0M, a 100% decline year-over-year.
- Merck net acquisitions/divestitures for the twelve months ending March 31, 2026 were $-4.093B, a 76.76% decline year-over-year.
- Merck annual net acquisitions/divestitures for 2024 were $-4.093B, a 65.98% decline from 2023.
- Merck annual net acquisitions/divestitures for 2023 were $-12.032B, a 0% decline from 2022.
- Merck annual net acquisitions/divestitures for 2022 were $0B, a 100% decline from 2021.
|
Merck Annual Net Acquisitions/Divestitures (Millions of US $) |
|
|---|---|
| 2024 | $-4,093 |
| 2023 | $-12,032 |
| 2022 | N/A |
| 2021 | $-12,907 |
| 2020 | $-6,606 |
| 2019 | $-4,954 |
| 2018 | $-431 |
| 2017 | $-396 |
| 2016 | $-780 |
| 2015 | $-7,428 |
| 2014 | $11,239 |
| 2013 | $-200 |
| 2012 | N/A |
| 2011 | $-50 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $299.893B | $65.011B |
| Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |